# Graceway Pharmaceuticals, LLC clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Graceway Pharmaceuticals, LLC as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Graceway Pharmaceuticals, LLC: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/graceway-pharmaceuticals-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 25, 2010 | NCT01055106 | Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Vaginosis, Bacterial, Vaginal Infection | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01055106) |
| May 7, 2009 | NCT00894647 | Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Actinic Keratosis | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00894647) |
| August 15, 2008 | NCT00735462 | Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Genital Warts | 511 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00735462) |
| May 8, 2008 | NCT00674739 | Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Genital Warts | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00674739) |
| April 29, 2008 | NCT00668733 | Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year | Graceway Pharmaceuticals, LLC | Observational | Completed | Actinic Keratoses | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00668733) |
| January 30, 2008 | NCT00605176 | Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs) | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Actinic Keratoses | 479 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00605176) |
| January 29, 2008 | NCT00603798 | Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Actinic Keratosis | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00603798) |
| June 9, 2006 | NCT00335179 | Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Actinic Keratosis | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00335179) |
| September 19, 2005 | NCT00189306 | Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Superficial Basal Cell Carcinoma | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189306) |
| August 12, 2005 | NCT00129519 | A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence | Graceway Pharmaceuticals, LLC | Phase 3 | Completed | Basal Cell Carcinoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00129519) |
| July 11, 2005 | NCT00117923 | Study With a Topical Gel to Treat Common Warts in Adults | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00117923) |
| July 11, 2005 | NCT00117871 | Study With a Topical Gel to Treat Common Warts in Adults | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00117871) |
| July 1, 2005 | NCT00116675 | Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00116675) |
| July 1, 2005 | NCT00116662 | An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00116662) |
| July 1, 2005 | NCT00116649 | Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis | Graceway Pharmaceuticals, LLC | Phase 4 | Completed | Keratosis | 551 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00116649) |
| June 22, 2005 | NCT00115154 | Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands | Graceway Pharmaceuticals, LLC | Phase 4 | Completed | Keratosis | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00115154) |
| June 22, 2005 | NCT00115141 | Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00115141) |
| June 21, 2005 | NCT00114920 | Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults | Graceway Pharmaceuticals, LLC | Phase 2 | Completed | Warts | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00114920) |
| June 17, 2005 | NCT00114673 | A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling | Graceway Pharmaceuticals, LLC | Observational | Completed | Skin Wrinkling | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00114673) |
| June 14, 2005 | NCT00114023 | 1-Year Follow up to the 1473-IMIQ Study | Graceway Pharmaceuticals, LLC | Observational | Completed | Keratosis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00114023) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 2 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Keratosis, Actinic | 8 |
| Warts | 6 |
| Skin Diseases | 4 |
| Keratosis | 3 |
| Condylomata Acuminata | 2 |
| Carcinoma, Basal Cell | 1 |
| Vaginosis, Bacterial | 1 |
| Vaginitis | 1 |
| Vaginal Discharge | 1 |
| Vaginal Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
